Biocon Limited

rs,

4, 2023 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

₹ 11,550

O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 2 2 Biocon at a Glance ₹ 11,550 Cr | $ ~1.4 bn Revenue* ~15,000+ Total Employees* Rank #8 Among Top 10 Global Biotech Employers*

rs 8

se global talent pool of 5,500+ people 965+ patents granted Portfolio comprises 20 biosimilars 8 Commercial Products in Global Markets >5M Patients served Unique, fully integrated leading glob

rs 1

products commercialized globally Hybrid model: Direct presence + Network of partners & distributors 1Two products are in-licensed i.e. Adalimumab & Etanercept B I O C O N L I M I T E D B I O C O N L I

rs 2

o drive sustainable growth B I O C O N B I O L O G I C S G R O W T H D R I V E R S Today < 2 years 2-4 years >4 years - Pegfilgrastim - Trastuzumab - Bevacizumab - Bevacizumab (US) - Aspart (US)

78 Billion

Global Markets 08 20 Biosimilars in our Portfolio Biocon Biologics’ portfolio targets a ~US$ 78 Billion addressable market by FY28 Note: Market size only includes products where there has been company r

38%

m syndicate of dedicated biotech investors ✓ $105M raised in Series B funding. Biocon ownership at 38%, to reduce to ~23% in FY24. ✓ Leveraging the Biocon and Syngene infrastructure to offer agility an

23%

cated biotech investors ✓ $105M raised in Series B funding. Biocon ownership at 38%, to reduce to ~23% in FY24. ✓ Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience i

1 %

Q4 FY23 Consolidated (in ₹ Cr.) Q4 FY23 Q4 FY22 YoY % Total Revenue 3,929 2,476 Core EBITDA1 % Margin EBITDA % Margin Profit Before Tax (Before exceptional charge) % Margin Net Profit (Bef

35%

exceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 1,260 35% 1,152 29% 500 13% 335 9% 809 33% 659 27% 384 15% 262 11% 59 56 75 30 28 Biosimi

29%

charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 1,260 35% 1,152 29% 500 13% 335 9% 809 33% 659 27% 384 15% 262 11% 59 56 75 30 28 Biosimilars +114% |

13%

% Margin Net Profit (Before exceptional charge) Net Profit Margin % 1,260 35% 1,152 29% 500 13% 335 9% 809 33% 659 27% 384 15% 262 11% 59 56 75 30 28 Biosimilars +114% | Research

Research Services

1

Research Services

Syngene’s broad capabilities, spanning the value chain, facilitate integration to capture additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centres Development Services Manufacturing Services Flexible Platform with capability across multiple modalities, including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs SynVent Syngene’s proprietary platform for Integrated Drug Discovery SARchitect- Syngene’s proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies Ring-fenced infrastructure for exclusive operations for an individual client Pre-clinical to clinical trials Manufacturing of small and large molecules for commercial supplies Dedicated, multi-disciplinary team of scientists Drug substance and drug product development for both large and small molecules Access